Compare Charles River Laboratories Intl. Inc (CRL) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Roundhill Magnificent Seven ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $287.5 (market cap $13.46B), while Roundhill Magnificent Seven ETF trades at $67.76. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Roundhill Magnificent Seven ETF nearer its low. Which is the better fit depends on your goals.
| CRL | MAGS | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Sector/Thematic |
52-Week High | $282.00 | $70.94 |
52-Week Low | $145.57 | $55.39 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
MAGS (Roundhill Magnificent Seven ETF) trades at $67.685, down 1.96% with technical indicators showing bullish moving averages but overbought RSI levels. The ETF faces headwinds as AI spending pressures tech balance sheets, with recent underperformance against the broader market. News sentiment highlights a shift away from concentrated tech exposure toward diversified sectors.
The outlook remains cautious as AI capital expenditures weigh on near-term returns, though long-term AI adoption potential persists. Key risks include tech concentration, valuation compression, and earnings growth sustainability. Investors should monitor broadening market trends and hyperscaler cash flow improvements for catalyst opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
